This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.
Emergent Biosolutions (EBS) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EBS or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EBS vs. ALKS: Which Stock Is the Better Value Option?
Emergent Completes Acquisition of Narcan Maker Adapt Pharma
by Zacks Equity Research
Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.
Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
by Zacks Equity Research
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M
by Zacks Equity Research
Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.
Emergent Biosolutions (EBS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 11.46% and 5.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
EBS vs. NEO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?
EBS vs. NEO: Which Stock Is the Better Value Option?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?
What Lies Ahead for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?
by Zacks Equity Research
Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?
by Zacks Equity Research
In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.
Will ACADIA (ACAD) Disappoint Investors This Earnings Season?
by Zacks Equity Research
ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?
by Zacks Equity Research
Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
by Zacks Equity Research
Let us look at the factors that have led to the increase in share price of Emergent (EBS).
Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.